Boutique Biotech

Boutique Biotech

Share this post

Boutique Biotech
Boutique Biotech
Affimed, Medicenna, and Karuna Therapeutics in the spotlight

Affimed, Medicenna, and Karuna Therapeutics in the spotlight

Sliding scales on $AFMD, $MDNA, and $KRTX

Bohdan (Bo) Khomtchouk, Ph.D.'s avatar
Bohdan (Bo) Khomtchouk, Ph.D.
Feb 23, 2023
∙ Paid

Share this post

Boutique Biotech
Boutique Biotech
Affimed, Medicenna, and Karuna Therapeutics in the spotlight
2
Share

Affimed has been on a dive, now trading under $1/share. At a recent Q&A, Affimed CEO gave additional details on the IND process with FDA to get AFM13+NK cells from partner Artiva into human trials. The planned trial has 2 phases:

  • Phase 1 of the trial will include 2 doses of NK cells. The lower dose will be 1 billion NK cells from Artiva and the higher do…

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Bohdan (Bo) Khomtchouk, Ph.D.
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share